Details of the Drug

General Information of Drug (ID: DMN3GCH)

Drug Name
Darunavir
Synonyms
206361-99-1; TMC114; Prezista; TMC-114; UIC-94017; Darunavirum; TMC 114; Darunavirum [INN-Latin]; UNII-YO603Y8113; AIDS073035; CHEMBL1323; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; CHEBI:367163; Darunavir-d9; YO603Y8113; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate; NCGC00168773-01; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl; Darunavirum; Darunavir [USAN]; UIC 94017; Prezista(TM); UIC-96017; Darunavir (USAN/INN); Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(330)oct-2-yloxy)carboxamide; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Human immunodeficiency virus-1 infection 1C62 Phase 3 [2]
Therapeutic Class
Antiviral Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 547.7
Topological Polar Surface Area (xlogp) 2.9
Rotatable Bond Count (rotbonds) 12
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 8.1 mg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 6 days [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 73-80% [3]
Clearance
The clearance of drug is 32.8 L/h [5]
Elimination
A mass balance study in healthy volunteers demonstrated that after single dose administration of 400 mg 14C-darunavir, given with 100 mg ritonavir, approximately 79.5% and 13.9% of the administered dose of radiolabeled darunavir was obtained in the feces and urine, respectively [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 15 hours [6]
Metabolism
The drug is metabolized via the hepatic cytochrome enzymes (mainly CYP3A) [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 20.8672 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.05% [9]
Vd
The volume of distribution (Vd) of drug is 206.5 L [10]
Water Solubility
The ability of drug to dissolve in water is measured as 0.15 mg/mL [4]
Chemical Identifiers
Formula
C27H37N3O7S
IUPAC Name
[(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
Canonical SMILES
CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N
InChI
InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1
InChIKey
CJBJHOAVZSMMDJ-HEXNFIEUSA-N
Cross-matching ID
PubChem CID
213039
ChEBI ID
CHEBI:367163
CAS Number
206361-99-1
DrugBank ID
DB01264
TTD ID
D03IGH
VARIDT ID
DR00514
INTEDE ID
DR0420
ACDINA ID
D00170

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Protease (HIV PR) TT5FNQT POL_HV1B1 Modulator [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [12]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [13]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Darunavir
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
MK-1439 DM215WE Minor Decreased metabolism of Darunavir caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [59]
Fostemsavir DM50ILT Moderate Decreased metabolism of Darunavir caused by Fostemsavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Dolutegravir DMCZGRE Minor Increased metabolism of Darunavir caused by Dolutegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [61]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Darunavir caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [62]
Maraviroc DMTL94F Major Decreased metabolism of Darunavir caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Coadministration of a Drug Treating the Disease Different from Darunavir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Darunavir and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [64]
Midostaurin DMI6E0R Moderate Decreased metabolism of Darunavir caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [65]
Arn-509 DMT81LZ Moderate Increased metabolism of Darunavir caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [66]
Gilteritinib DMWQ4MZ Moderate Decreased metabolism of Darunavir caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [67]
Oliceridine DM6MDCF Major Decreased metabolism of Darunavir caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [68]
Ivabradine DM0L594 Major Decreased metabolism of Darunavir caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [64]
Dronedarone DMA8FS5 Major Decreased metabolism of Darunavir caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [64]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Darunavir and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [69]
Cariprazine DMJYDVK Moderate Decreased metabolism of Darunavir caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [70]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Darunavir and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [71]
Talazoparib DM1KS78 Moderate Decreased clearance of Darunavir due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [67]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Darunavir caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [72]
HKI-272 DM6QOVN Major Decreased metabolism of Darunavir caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [73]
LY2835219 DM93VBZ Moderate Decreased metabolism of Darunavir caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [74]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Darunavir caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [62]
Tucatinib DMBESUA Moderate Decreased metabolism of Darunavir caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [75]
Palbociclib DMD7L94 Moderate Decreased metabolism of Darunavir caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [67]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Darunavir caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [62]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Darunavir caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [76]
Bosutinib DMTI8YE Major Decreased metabolism of Darunavir caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [64]
Macitentan DMP79A1 Moderate Decreased metabolism of Darunavir caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [77]
PF-04449913 DMSB068 Moderate Decreased metabolism of Darunavir caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [78]
Revefenacin DMMP5SI Moderate Decreased clearance of Darunavir due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [79]
Indacaterol DMQJHR7 Minor Decreased metabolism of Darunavir caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [80]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Darunavir caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [62]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Darunavir caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [62]
Ulipristal DMBNI20 Minor Decreased metabolism of Darunavir caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [67]
Mestranol DMG3F94 Moderate Decreased metabolism of Darunavir caused by Mestranol mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [62]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Darunavir caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [67]
Ivacaftor DMZC1HS Major Decreased metabolism of Darunavir caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [67]
MK-8228 DMOB58Q Moderate Decreased metabolism of Darunavir caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [81]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Darunavir caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [64]
Vilazodone DM4LECQ Moderate Decreased metabolism of Darunavir caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [82]
OPC-34712 DMHG57U Major Decreased metabolism of Darunavir caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [83]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Darunavir caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [84]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Darunavir caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [62]
Cenobamate DMGOVHA Moderate Increased metabolism of Darunavir caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [66]
Stiripentol DMMSDOY Moderate Decreased metabolism of Darunavir caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [67]
Fosphenytoin DMOX3LB Major Increased metabolism of Darunavir caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [85]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Darunavir caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [66]
Cannabidiol DM0659E Minor Decreased metabolism of Darunavir caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [67]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Darunavir caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [86]
Tazemetostat DMWP1BH Major Decreased metabolism of Darunavir caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [87]
Solifenacin DMG592Q Moderate Decreased metabolism of Darunavir caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [88]
Mirabegron DMS1GYT Minor Decreased metabolism of Darunavir caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [89]
Ripretinib DM958QB Moderate Decreased metabolism of Darunavir caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [64]
Avapritinib DMK2GZX Major Decreased metabolism of Darunavir caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [67]
Colchicine DM2POTE Major Decreased metabolism of Darunavir caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [90]
Simeprevir DMLUA9D Major Decreased metabolism of Darunavir caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [64]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Darunavir caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [64]
GS-9857 DMYU6P5 Moderate Decreased clearance of Darunavir due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [91]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Darunavir and Brentuximab vedotin. Hodgkin lymphoma [2B30] [92]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Darunavir and Mipomersen. Hyper-lipoproteinaemia [5C80] [93]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Darunavir and Teriflunomide. Hyper-lipoproteinaemia [5C80] [85]
BMS-201038 DMQTAGO Major Decreased metabolism of Darunavir caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [64]
Aliskiren DM1BV7W Moderate Decreased metabolism of Darunavir caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [85]
Levamlodipine DM92S6N Moderate Decreased metabolism of Darunavir caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [85]
Suvorexant DM0E6S3 Major Decreased metabolism of Darunavir caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [94]
Amobarbital DM0GQ8N Moderate Increased metabolism of Darunavir caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [66]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Darunavir caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [95]
ITI-007 DMUQ1DO Major Decreased metabolism of Darunavir caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [96]
Naloxegol DML0B41 Major Decreased metabolism of Darunavir caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [64]
Pemigatinib DM819JF Major Decreased metabolism of Darunavir caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [67]
Crizotinib DM4F29C Moderate Decreased metabolism of Darunavir caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [97]
Brigatinib DM7W94S Major Decreased metabolism of Darunavir caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [64]
Ceritinib DMB920Z Moderate Decreased metabolism of Darunavir caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [98]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Darunavir caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [99]
Osimertinib DMRJLAT Moderate Decreased metabolism of Darunavir caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [100]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Darunavir caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [101]
Capmatinib DMYCXKL Moderate Decreased metabolism of Darunavir caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [102]
Selpercatinib DMZR15V Major Decreased metabolism of Darunavir caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [67]
Artemether DM48QOT Major Decreased metabolism of Darunavir caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [64]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Darunavir caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [64]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Darunavir and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [103]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Darunavir and Idelalisib. Mature B-cell leukaemia [2A82] [104]
GDC-0199 DMH0QKA Major Decreased metabolism of Darunavir caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [64]
IPI-145 DMWA24P Moderate Decreased metabolism of Darunavir caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [105]
Ibrutinib DMHZCPO Major Decreased metabolism of Darunavir caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [106]
Vemurafenib DM62UG5 Moderate Increased metabolism of Darunavir caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [66]
Selumetinib DMC7W6R Major Decreased metabolism of Darunavir caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [107]
LGX818 DMNQXV8 Major Decreased metabolism of Darunavir caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [108]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Darunavir caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [66]
Rimegepant DMHOAUG Moderate Decreased metabolism of Darunavir caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [109]
Exjade DMHPRWG Moderate Decreased metabolism of Darunavir caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [110]
Flibanserin DM70DTN Major Decreased metabolism of Darunavir caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [111]
Panobinostat DM58WKG Moderate Decreased metabolism of Darunavir caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [112]
Deflazacort DMV0RNS Major Decreased metabolism of Darunavir caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [67]
Fedratinib DM4ZBK6 Minor Decreased metabolism of Darunavir caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [67]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Darunavir caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [67]
Entrectinib DMMPTLH Major Decreased metabolism of Darunavir caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [64]
S-297995 DM26IH8 Moderate Decreased metabolism of Darunavir caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [67]
Olaparib DM8QB1D Major Decreased metabolism of Darunavir caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [64]
Istradefylline DM20VSK Moderate Decreased metabolism of Darunavir caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [113]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Darunavir caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [114]
Abametapir DM2RX0I Moderate Decreased metabolism of Darunavir caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [115]
Lefamulin DME6G97 Moderate Decreased metabolism of Darunavir caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [116]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Darunavir caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [117]
Darolutamide DMV7YFT Minor Decreased metabolism of Darunavir caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [118]
Silodosin DMJSBT6 Moderate Decreased metabolism of Darunavir caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [119]
Everolimus DM8X2EH Major Decreased clearance of Darunavir due to the transporter inhibition by Everolimus. Renal cell carcinoma [2C90] [120]
Axitinib DMGVH6N Moderate Decreased metabolism of Darunavir caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [67]
Temsirolimus DMS104F Moderate Decreased metabolism of Darunavir caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [121]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Darunavir caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [122]
Upadacitinib DM32B5U Moderate Decreased metabolism of Darunavir caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [123]
Tofacitinib DMBS370 Moderate Decreased metabolism of Darunavir caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [64]
Iloperidone DM6AUFY Moderate Decreased metabolism of Darunavir caused by Iloperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [62]
Avanafil DM75CXN Major Decreased metabolism of Darunavir caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [124]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Darunavir caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [125]
LDE225 DMM9F25 Major Decreased metabolism of Darunavir caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [126]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Darunavir caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [67]
Larotrectinib DM26CQR Moderate Decreased metabolism of Darunavir caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [64]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Darunavir and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [67]
Armodafinil DMGB035 Minor Decreased metabolism of Darunavir caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [64]
Pitolisant DM8RFNJ Moderate Increased metabolism of Darunavir caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [67]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Darunavir caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [127]
Apixaban DM89JLN Moderate Decreased metabolism of Darunavir caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [64]
Brilinta DMBR01X Moderate Decreased metabolism of Darunavir caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [67]
Cabozantinib DMIYDT4 Moderate Decreased metabolism of Darunavir caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [128]
Elagolix DMB2C0E Moderate Increased metabolism of Darunavir caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [66]
Fluticasone DMGCSVF Moderate Decreased metabolism of Darunavir caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [64]
⏷ Show the Full List of 120 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sunset yellow FCF E00255 17730 Colorant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Darunavir 400 mg tablet 400 mg Oral Tablet Oral
Darunavir 600 mg tablet 600 mg Oral Tablet Oral
Darunavir 800 mg tablet 800 mg Oral Tablet Oral
Darunavir 150 mg tablet 150 mg Oral Tablet Oral
Darunavir 75 mg tablet 75 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 FDA Approves ILUMYA (tildrakizumab-asmn) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy
4 BDDCS applied to over 900 drugs
5 Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, van Hoof B, Raoof A: Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos. 2009 Apr;37(4):809-20. doi: 10.1124/dmd.108.024109. Epub 2009 Jan 8.
6 Darunavir: pharmacokinetics and drug interactions. Antivir Ther. 2008;13(1):1-13.
7 FDA Approved Drug Products: Prezista (darunavir) oral tablets/suspension
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 Larson KB, Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Acosta EP: Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults. J Pediatric Infect Dis Soc. 2016 Jun;5(2):131-7. doi: 10.1093/jpids/piu142. Epub 2015 Jan 28.
11 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
12 P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull. 2009 Sep;32(9):1588-93.
13 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
14 Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother. 2010 Nov;65(11):2319-28.
15 Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet. 2009;48(4):211-41.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
26 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
27 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
28 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
29 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
30 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
31 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
32 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
33 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
34 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
35 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
36 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
37 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
38 FDA Drug Development and Drug Interactions
39 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
40 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
41 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
42 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
43 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
44 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
45 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
46 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
47 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
48 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
49 PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63.
50 Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80.
51 Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20.
52 Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9.
53 Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.
54 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
55 Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410.
56 2011 Pipeline of Boehringer Ingelheim Pharma.
57 2011 Pipeline of Bristol-Myers Squibb.
58 2011 Pipeline of InterMune.
59 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
60 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
61 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
62 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
63 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
64 Cerner Multum, Inc. "Australian Product Information.".
65 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
66 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
67 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
68 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
69 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
70 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
71 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
72 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
73 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
74 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
75 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
76 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
77 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
78 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
79 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
80 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
81 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
82 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
83 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
84 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
85 Canadian Pharmacists Association.
86 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
87 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
88 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
89 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
90 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
91 Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead Sciences, Foster City, CA.
92 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
93 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
94 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
95 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
96 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
97 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
98 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
99 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
100 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
101 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
102 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
103 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
104 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
105 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
106 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
107 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
108 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
109 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
110 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
111 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
112 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
113 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
114 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
115 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
116 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
117 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
118 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
119 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
120 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
121 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
122 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
123 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
124 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
125 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
126 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
127 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
128 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.